Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q4 FY19 results · Jan–Mar 2019
Bliss GVS Pharma reported revenue from operations of ₹244.05 crore and net profit of ₹18.79 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 244.05 | — | — | 220.43 | +10.7% |
| Other income | 2.79 | — | — | (3.90) | Turned profit |
| Total income | 246.84 | — | — | 216.53 | +14.0% |
| Profit before tax | 31.60 | — | — | 36.48 | −13.4% |
| Net profit for the period | 18.79 | — | — | 27.23 | −31.0% |
| Attributable to shareholders of the company | 18.11 | — | — | 25.84 | −29.9% |
| EPS, basic (₹) | 1.76 | — | — | 2.50 | −29.6% |
| Net margin (%) | 7.7 | — | 12.4 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 106.14 | — | — | 95.63 | +11.0% |
| Other income | 3.02 | — | — | (4.35) | Turned profit |
| Total income | 109.16 | — | — | 91.28 | +19.6% |
| Profit before tax | 14.86 | — | — | 18.27 | −18.7% |
| Net profit for the period | 4.64 | — | — | 11.70 | −60.3% |
| EPS, basic (₹) | 0.45 | — | — | 1.13 | −60.2% |
| Net margin (%) | 4.4 | — | 12.2 |
Consolidated
- Filed with BSE
- 21 May 2019, 14:46 IST
- Board meeting
- 18 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 May 2019, 14:46 IST
- Board meeting
- 18 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE